Overview

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Status:
RECRUITING

Trial end date:
2029-01-29

Target enrollment:

Participant gender:

Summary

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

Phase:

PHASE3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Daiichi Sankyo

Treatments:

Docetaxel